A Study of Galcanezumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

September 3, 2016

Study Completion Date

January 8, 2018

Conditions

Healthy

Interventions

DRUG

Galcanezumab

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

Covance, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02576951 - A Study of Galcanezumab in Healthy Participants | Biotech Hunter | Biotech Hunter